Tarsus Pharmaceuticals Inc
$ 76.20
-0.46%
04 Mar - close price
- Market Cap 3,257,776,000 USD
- Current Price $ 76.20
- High / Low $ 78.12 / 75.86
- Stock P/E N/A
- Book Value 8.07
- EPS -1.59
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.23 %
- 52 Week High 85.25
- 52 Week Low 38.51
About
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Analyst Target Price
$94.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-09 | 2023-08-10 | 2023-05-09 | 2023-03-13 |
| Reported EPS | -0.3 | -0.48 | -0.64 | -0.6 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 | -1.17 | -0.88 | -0.49 |
| Estimated EPS | -0.35 | -0.38 | -0.63 | -0.8157 | -0.94 | -0.92 | -1.2 | -1.36 | -1.37 | -1.08 | -0.94 | -0.69 |
| Surprise | 0.05 | -0.1 | -0.01 | 0.2157 | 0.33 | 0.04 | 0.19 | 0.05 | 0.09 | -0.09 | 0.06 | 0.2 |
| Surprise Percentage | 14.2857% | -26.3158% | -1.5873% | 26.4435% | 35.1064% | 4.3478% | 15.8333% | 3.6765% | 6.5693% | -8.3333% | 6.383% | 28.9855% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.0836 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARS
2026-03-04 15:53:28
This article reports on a Form 144 SEC filing by Tarsus Pharmaceuticals, Inc. (TARS), indicating a proposed sale of securities. The filing details information about the issuer, the person for whom the securities are to be sold, and the specifics of the securities to be sold, including the acquisition date and nature of acquisition. The document also includes a mandatory disclaimer regarding material adverse information and a signature section.
2026-03-03 16:52:19
Tarsus Pharmaceuticals (TARS) is highlighted as a promising investment in the biopharmaceutical industry, focusing on eye care therapeutics with a potential upside of 21.88%. The company is recognized for its flagship product XDEMVY for demodex blepharitis and a strong pipeline, backed by bullish analyst ratings and positive technical indicators despite current negative EPS and ROE. Strategic collaborations and robust revenue growth further strengthen its market position for discerning investors.
2026-03-03 16:52:19
Tarsus Pharmaceuticals recently reported strong 2025 results with US$451.36 million in revenue and filed a US$141.73 million shelf registration, leading to a significant recovery in its share price. Despite being up strongly, the stock, currently at US$75.52, is considered undervalued with a fair value estimate of US$87.50, driven by rapid revenue expansion and potential future profitability. However, continued success depends on strong uptake of XDEMVY and effective sales and marketing, as its P/S ratio indicates a tighter margin for error compared to its discounted cash flow valuation.
2026-03-02 15:51:38
Tarsus Pharmaceuticals (TARS) recently reported strong 2025 results with US$451.36 million in revenue and a net loss of US$66.42 million, alongside filing a US$141.73 million shelf registration. Despite a negative year-to-date return, the stock has seen significant gains over the past year. The article analyzes Tarsus's valuation, suggesting it is significantly undervalued based on a DCF model, but notes a tighter margin for error when considering its P/S ratio compared to peers.
2026-03-02 13:51:38
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) has successfully passed a "High Growth Momentum + Trend Template" screen, indicating its strong technical and fundamental performance. The company fits the Minervini Trend Template due to its moving average order, proximity to 52-week highs, and strong relative strength. Furthermore, TARS exhibits high revenue growth and improving earnings, driven by the sales of its lead product XDEMVY.
2026-03-01 08:55:13
Artisan Partners Limited Partnership increased its holdings in Tarsus Pharmaceuticals (NASDAQ:TARS) by 3.5% in the third quarter, now owning 558,326 shares valued at $33.18 million. The article highlights mixed analyst ratings, with some boosting price targets and others downgrading. Tarsus Pharmaceuticals reported revenue above estimates but missed EPS, and saw insider selling from its CEO and other insiders.
